As a typical dibenzylisoquinoline alkaloid, tetrandrine (TET) is clinically used for the treatment of silicosis, inflammatory pulmonary, and cardiovascular diseases in China. Recent investigations have demonstrated the outstanding anticancer activity of this structure, but its poor aqueous solubility severely restricts its further development. Herein, a series of its 14--amino acid-substituted derivatives with improved anticancer effects and aqueous solubility were designed and synthesized. Among them, compound displayed the best antiproliferative activity against human colorectal cancer (HCT-15) cells, with an IC value of 0.57 μM. Compared with TET, was markedly improved in terms of aqueous solubility (by 5-fold). Compound significantly suppressed the colony formation, migration, and invasion of HCT-15 cells in a concentration-dependent manner, with it being more potent in this respect than TET. Additionally, compound markedly impaired the morphology and motility of HCT-15 cells and induced the death of colorectal cancer cells in double-staining and flow cytometry assays. Western blot results revealed that could induce the autophagy of HCT-15 cells by significantly decreasing the content of p62/SQSTM1 and enhancing the Beclin-1 level and the ratio of LC3-II to LC3-I. Further study showed that effectively inhibited the proliferation, migration, and tube formation of umbilical vein endothelial cells, manifesting in a potent anti-angiogenesis effect. Overall, these results revealed the potential of as a promising candidate for further preclinical studies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268013 | PMC |
http://dx.doi.org/10.3390/molecules27134040 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!